Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on LinkedIn:
“FIRE-4 Trial Confirms the Clinical Relevance of Liquid Biopsy in Metastatic Colorectal Cancer!!!
New findings from the phase III FIRE-4 trial, published JCO confirm that liquid biopsy accurately identifies RAS/BRAF V600E mutations in metastatic colorectal cancer (mCRC), offering critical insights before treatment.
– Accurate Molecular Profiling: Liquid biopsy aligns with tissue-based analysis.
– Impact on Survival: RAS-mutant patients had shorter PFS and OS.
– Treatment Insights: Early switch maintenance therapy benefited RAS-mutant patients.
– Tumor Evolution: Higher RAS mutation conversion with continuous cetuximab.”
Read full article at the ASCO Post.